Source: Health Canada shortage reports · Updated Sep 1, 2026
Some Dabigatran Etexilate products are in shortage in Canada (2 of 6 reported products), while others remain available. Your pharmacy may be able to substitute an unaffected manufacturer. The latest estimate for affected products to return is Oct 23, 2026.
A blood thinner (direct thrombin inhibitor) used to prevent and treat blood clots and stroke.
Products affected
2 / 6
In shortage since
Oct 22, 2024
Est. full return
Oct 23, 2026
Reports on file
32
Talk to a pharmacist
Pharmacists can substitute an unaffected manufacturer's version, adjust strengths, and in most provinces adapt or renew a prescription on the spot.
Independent services, not affiliated with rxstat; referral fees may apply. Free options exist depending on your province. In an emergency call 911; free health advice at 811.
Shortage history
Shortage history (red bands = periods in shortage).
Reports by product
The DIN is printed on your prescription label.
Active shortage
APO-DABIGATRAN
110MG · CAPSULE · APOTEX INC
DIN 02468905 · since Aug 18, 2026, est. end Oct 23, 2026 · Disruption of the manufacture of the drug.
Active shortage
APO-DABIGATRAN
110MG · CAPSULE · APOTEX INC
DIN 02468905 · since Nov 12, 2024, no end estimate · Disruption of the manufacture of the drug.
Active shortage
APO-DABIGATRAN
150MG · CAPSULE · APOTEX INC
DIN 02468913 · since Oct 22, 2024, no end estimate · Disruption of the manufacture of the drug.
Anticipated
APO-DABIGATRAN
150MG · CAPSULE · APOTEX INC
DIN 02468913 · Disruption of the manufacture of the drug.
Resolved
APO-DABIGATRAN
110MG · CAPSULE · APOTEX INC
DIN 02468905 · ended Jun 5, 2026 · Disruption of the manufacture of the drug.
DIN 02468905 · ended May 22, 2025 · Disruption of the manufacture of the drug.
Resolved
APO-DABIGATRAN
110MG · CAPSULE · APOTEX INC
DIN 02468905 · ended Jan 23, 2025 · Disruption of the manufacture of the drug.
Resolved
APO-DABIGATRAN
150MG · CAPSULE · APOTEX INC
DIN 02468913 · ended Sep 19, 2024 · Disruption of the manufacture of the drug.
Resolved
APO-DABIGATRAN
110MG · CAPSULE · APOTEX INC
DIN 02468905 · ended Sep 19, 2024 · Disruption of the manufacture of the drug.
Resolved
APO-DABIGATRAN
150MG · CAPSULE · APOTEX INC
DIN 02468913 · ended Jul 18, 2024 · Disruption of the manufacture of the drug.
Resolved
APO-DABIGATRAN
75MG · CAPSULE · APOTEX INC
DIN 02468891 · ended Jul 18, 2024 · Disruption of the manufacture of the drug.
Showing 12 of 32 reports. All reports are on file with Health Canada.
What's happening
Dabigatran Etexilate is currently affected by 2 active shortage reports filed with Health Canada by APOTEX INC.
The reported cause is: disruption of the manufacture of the drug. Manufacturers must report shortages, but end-date estimates are their own projections and often move.
If your usual product is affected, a pharmacist is the fastest route to a solution: they can dispense an unaffected manufacturer's equivalent when one exists, and in most provinces can adapt doses or substitute a therapeutic alternative without a new appointment.
Dabigatran Etexilate is classified under “ANTITHROMBOTIC AGENTS” (ATC B01AE).
Recent changes
Sep 1, 2026
New report filed
Aug 27, 2026
Estimated end date pushed back : Oct 16, 2026 → Oct 23, 2026
Aug 24, 2026
Shortage resolved
Aug 21, 2026
New report filed
Common questions
What is Dabigatran Etexilate used for?
A blood thinner (direct thrombin inhibitor) used to prevent and treat blood clots and stroke.
When will Dabigatran Etexilate be back in stock in Canada?
The latest manufacturer estimate is Oct 23, 2026. Estimates are self-reported and often slip; this page updates automatically when they change.
Why is Dabigatran Etexilate in shortage?
See the reports above; manufacturers must state a reason (most commonly manufacturing disruption or a surge in demand) when filing with Health Canada.
What can my pharmacist do about it?
Often quite a lot: substitute an equivalent product from an unaffected manufacturer, adjust quantities, or in most provinces adapt or renew prescriptions on the spot. Call your pharmacy before visiting, and call 811 for free health advice.
Email alerts
Get an email when this drug's status changes. Double opt-in, one-click unsubscribe.
Drugs in the same therapeutic class, best-supplied first. These are not automatic substitutes: only your pharmacist or prescriber can judge whether a switch makes sense for you.
Data reflects reports manufacturers are legally required to file with Health Canada, republished with per-drug aggregation by rxstat. Estimated end dates are supplied by manufacturers and frequently change. This page describes drug supply only and is not medical advice; never stop or switch a medication without speaking to your pharmacist or prescriber.